Since recent observations show that targeting the EGFR signaling pathway can also trigger immunogenic cell death 12 or influence the tumor immune environment via the JAK/STAT3 axis, possible effects for immunotherapy or combination therapy are also of great interest. Here, EGFR is linked to neoplasm.